B-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-06-05Clinical Trial Update: T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia [Phase 1]
This clinical trial update describes a Phase 1 study evaluating autologous CD19-targeted CAR-T cells in pediatric and young adult patients w…
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies [Phase 1]
Phase 1 study evaluating CD19/CD22 CAR T cells in children and young adults with recurrent or refractory CD19/CD22-expressing B cell maligna…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) [EARLY_Phase 1]
This early-phase 1 trial investigates a dual-targeting CD19-CD22 CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic le…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia [Phase 1]
A Phase 1 trial of a triple-targeted CD19/CD20/CD22 CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia has been …
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL [Phase 2]
A Phase 2 study evaluating huCART19 for very high-risk pediatric B-cell acute lymphoblastic leukemia has completed and results have been pos…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia [Phase 1]
This Phase 1 trial update reports completion of a study evaluating the combination of palbociclib and dexamethasone in relapsed or refractor…
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia [NA]
A clinical trial update indicates that JY231 injections are being studied for relapsed/refractory B-cell acute lymphoblastic leukemia and B-…
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: Blinatumomab Bridging Therapy for BALL [Phase 2]
Phase 2 trial evaluating blinatumomab as bridging therapy for B-cell acute lymphoblastic leukemia was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Observational Study of Blinatumomab
An observational study evaluating Blinatumomab (Blincyto) in routine clinical practice has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia [NA]
A clinical trial entry for JY231 injection in relapsed or refractory B-cell acute lymphoblastic leukemia, currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-02-05Clinical Trial Update: Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL [Phase 1]
A Phase 1 trial evaluating blinatumomab in combination with HLA-mismatched cellular therapy for relapsed/refractory CD19+ B-cell acute lymph…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
A completed clinical trial evaluated the outcomes of adults with relapsed/refractory B-cell acute lymphoblastic leukemia treated with inotuz…
-
CLINICAL_TRIALS trial_result · 2025-01-23Clinical Trial Update: The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia [EARLY_Phase 1]
Early-phase clinical trial update on RD06-03 CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia; the study is cu…
-
CLINICAL_TRIALS trial_result · 2024-11-05Clinical Trial Update: Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. [Phase 2]
A phase 2 trial is evaluating combining Inaticabtagene Autoleucel CAR-T therapy with autologous hematopoietic stem cell transplantation in a…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL [Phase 2]
A Phase 2 trial evaluating sequential CD19 and CD22 CAR-T therapy for newly diagnosed Philadelphia chromosome–positive B-cell acute lymphobl…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL [Phase 2]
A Phase 2 trial evaluating reduced-dose chemotherapy followed by blinatumomab as induction therapy for newly diagnosed Philadelphia-negative…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations [Phase 3]
Phase 3 clinical trial update evaluating combination chemotherapy in young patients with newly diagnosed high-risk B-cell acute lymphoblasti…
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. [Phase 1, Phase 2]
Phase 1/2 clinical trial investigating a CD19/CD22-targeted CAR-T therapy for B-cell acute lymphoblastic leukemia (B-ALL).
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL [Phase 1, Phase 2]
Clinical trial update for CD19-targeted T-CAR therapy in children and young adults with relapsed/refractory B-ALL, currently in Phase 1/Phas…
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL [Phase 1, Phase 2]
Clinical trial evaluating a bispecific CD19/CD22 CAR-T therapy for children and young adults with refractory/relapsed B-ALL, across Phase 1 …
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia [Phase 2]
A Phase 2 trial evaluating Blinatumomab with either combination chemotherapy or Dasatinib, Prednisone, and Blinatumomab in older patients wi…
-
CLINICAL_TRIALS trial_result · 2022-12-08Clinical Trial Update: Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL [Phase 1, Phase 2]
A Phase 1/2 trial of novel anti-CD19 universal CAR-T cells for relapsed/refractory CD19+ B-cell acute lymphoblastic leukemia (B-ALL).
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia [Phase 3]
Phase 3 trial results for blinatumomab in younger patients with relapsed B-cell acute lymphoblastic leukemia have been posted.
-
CLINICAL_TRIALS trial_result · 2022-11-02Clinical Trial Update: Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL [Phase 2]
Phase 2 trial evaluating inotuzumab ozogamicin with conventional chemotherapy in adults 56 and older with precursor cell lymphoblastic leuke…
-
CLINICAL_TRIALS trial_result · 2022-09-29Clinical Trial Update: Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL [Phase 2]
Phase 2 trial investigating blinatumomab as a bridge to allogeneic hematopoietic stem cell transplantation in relapsed/refractory B-cell acu…